Board of Directors

Chairman - Professor Colin Chapman

Professor Colin Chapman BPharm BVSc (Hons) PhD FPS is a former Dean of the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University (1991 – 2006) and is now Professional Fellow at the Australian Health Workforce Institute, University of Melbourne. His current research interests are focused on drug development, immunology, dermatology and veterinary pharmacology. His PhD was obtained following research centred on immunology at the Walter and Eliza Hall Institute in Melbourne and he has maintained a keen professional interest and involvement in all aspects of immunology ever since. During his period as Dean of the Faculty of Pharmacy he played a key role in the commercialisation of Relenza®, a drug to prevent/treat influenza, and in the establishment of Acrux, a company formed to commercialise transdermal drug delivery techniques developed in the Faculty of Pharmacy.

Non-Executive Director - Dr. Elane Zelcer

Elane Zelcer BSc (Hons), PhD, Grad Dip Mktg, FAICD is an experienced business leader in the biotechnology sector. She has experience in executive, board and advisory roles in universities, CRCs, the private sector and on State and Federal government committees. Dr Zelcer is currently the Executive Director of BioConsult Pty Ltd which focuses on assisting early stage companies to develop their intellectual property through strategic partnering, capital raisings and collaboration. Dr Zelcer is also the CEO for Hadassah Australia. Dr Zelcer also chaired the Victorian State Government Bioeconomy Working Group; part of the State Government’s Biotechnology Strategy.

Non-Executive Director - Dr. Stewart Washer

Dr Washer has 20 years experience in negotiating successful commercial partnerships and license agreements in Australia and the rest of the world. He has 15 years’ senior executive and board experience in commercial technology companies in the medical, functional food and industrial biotech sectors.  He has raised over $50 million in private shareholder and government funds to invest in his companies and was a founder of a $120 million life science fund.  Dr Washer is currently a non-executive Director of Healthlinx Ltd (ASX: HTX). He was previously Chairman of of Resonance Health Ltd (ASX: RHT) and Hatchtech Pty Ltd, a Director of iCeutica Pty Ltd and AusBiotech Ltd and a member of Senate at Murdoch University. He was recently the Chief Executive Officer of Calzada Ltd (ASX:CZD) and the founding Chief Executive Officer of Phylogica Ltd (ASX:PYC) and before this, he was Chief Executive Officer of Celentis where he managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He has a Bachelor of Science and PhD in Biological Science.